Background Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the function of the naturally occurring GLP-1 hormone that is secreted in the gut following food intake
Hypoglycemia has been observed in patients treated with semaglutide at doses of 0.5 and 1 mg in combination with insulin
The most common adverse effects are gastrointestinal in nature and typically diminish as your body readjusts to the medication over several weeks
While berberine has shown modest metabolic benefits in clinical studies, GLP-1 receptor agonists like semaglutide produce weight reductions of 1522% in clinical trials, addressing hunger signals at the neurological level
Ozempic is FDA approved to treat type 2 diabetes
(Wegovy is approved to help with weight management in people with overweight or obesity.) Currently, there arent any formal studies on Ozempic butt. The term primarily comes from social media posts and blog articles, including some by plastic surgeons